Company profile for Caldera Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Caldera Therapeutics is a clinical-stage biotech advancing CLD-423, a first-in-class bispecific antibody targeting IL-23p19 and TL1A for IBD and inflammatory diseases. Founded in 2025 and based in Cambridge, MA, it launched with $112.5M from Atlas Venture, LAV, venBio, Omega Funds, Wellington, and Janus Henderson. Led by CEO Praveen Tipirneni (ex-Morphic), Phase 1 trials are dosing, promising superior efficacy beyond single-ta...
Caldera Therapeutics is a clinical-stage biotech advancing CLD-423, a first-in-class bispecific antibody targeting IL-23p19 and TL1A for IBD and inflammatory diseases. Founded in 2025 and based in Cambridge, MA, it launched with $112.5M from Atlas Venture, LAV, venBio, Omega Funds, Wellington, and Janus Henderson. Led by CEO Praveen Tipirneni (ex-Morphic), Phase 1 trials are dosing, promising superior efficacy beyond single-target therapies.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
300 Technology Square, 8th Floor, Cambridge, MA 02139
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

BPI Europe

BPI Europe

Not Confirmed

envelop Contact Supplier

BPI Europe

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercebiotech.com/biotech/caldera-launches-112m-former-morphic-ceo-and-ibd-drug-china

FIERCE BIOTECH
14 Jan 2026

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty